News
EVO
3.090
-0.64%
-0.020
Evotec Strengthens Supervisory Board and Strikes Governance Pact With MAK Capital
TipRanks · 1d ago
JPMorgan Chase cuts Evotec voting rights to 4.98% from 5.05%
PUBT · 1d ago
Evotec Receives Two Gates Foundation Grants Totalling $9.9M To Advance Novel Tuberculosis Drug Discovery And Clinical Combination Regimens
Benzinga · 2d ago
Evotec wins $ 9.9 million Gates Foundation grants for tuberculosis drug development
PUBT · 2d ago
BRIEF-Evotec Receives Two Gates Foundation Grants For TB Totaling $9.9 Million
Reuters · 2d ago
Evotec signs cooperation deal with activist MAK Capital ahead of June 11 AGM
PUBT · 2d ago
Evotec to Webcast First-Quarter Results and Business Update
PUBT · 3d ago
Weekly Report: what happened at EVO last week (0420-0424)?
Weekly Report · 5d ago
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 04/24 12:03
Goldman Sachs raises Evotec voting rights to 7.3% from 7.06%
PUBT · 04/24 11:52
Evotec Announces CFO Transition as Hitchin Departs and Hinshelwood Steps In
TipRanks · 04/24 10:30
Evotec CFO Paul Hitchin to step down, Claire Hinshelwood to succeed
TipRanks · 04/24 09:10
Evotec CFO Paul Hitchin Resigns; Names Claire Hinshelwood Replacement
NASDAQ · 04/24 06:22
Evotec names Claire Hinshelwood CFO, replacing Paul Hitchin from May 1
PUBT · 04/24 05:31
Evotec publishes company presentation outlining drug discovery strategy and value-creation levers
PUBT · 04/22 17:04
JPMorgan Chase cuts Evotec voting stake to 5.1% from 5.4%
PUBT · 04/21 12:43
Evotec (0IRF) Gets a Buy from RBC Capital
TipRanks · 04/21 03:25
Evotec publishes 2025 remuneration report ahead of June 11, 2026 AGM vote
PUBT · 04/20 16:12
Weekly Report: what happened at EVO last week (0413-0417)?
Weekly Report · 04/20 09:46
Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Legend Biotech (LEGN) and Inogen (INGN)
TipRanks · 04/15 10:20
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.